Nimodipine
4 NDCs across 2 manufacturers|4 Generic,0 Brand
Nimodipine is used to treat subarachnoid hemorrhage, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 28, 1988, and the first generic was approved Apr 17, 2007. FDA's Orange Book lists 5 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $797K on Nimodipine across 2,342 claims for 1,121 beneficiaries.
Nimodipine is available as 4 NDCs from 2 manufacturers (4 generic, 0 brand), with NADAC prices from $1.37 to $1.37 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
4G / 0B
Manufacturers
2
competing in market
Price Spread
$1.37 – $1.37
per EA
7d Activity
avg +9.2% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Heritage Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Dihydropyridine Calcium Channel Blocker class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing NIMODIPINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
NIMODIPINE 30 MG CAPSULE | $1.3695 per EA | +9.19% |
NIMODIPINE 30 MG CAPSULE | $1.3695 per EA | +9.19% |
NIMODIPINE 30 MG CAPSULE | $1.3695 per EA | +9.19% |
NIMODIPINE 30 MG CAPSULE | $1.3695 per EA | +9.19% |
Frequently Asked Questions
What is Nimodipine used to treat?
Nimodipine is used to treat subarachnoid hemorrhage, per the National Library of Medicine's MED-RT classification.
When did Nimodipine become available as a generic?
FDA approved the first generic Nimodipine (ANDA) on Apr 17, 2007. The Orange Book currently lists 5 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Nimodipine?
In 2024, Medicare Part D spent $797K on Nimodipine across 2,342 claims for 1,121 beneficiaries.
How many Nimodipine products are on the market?
The Nimodipine drug market contains 4 NDCs from 2 manufacturers — 4 generic and 0 brand products.
What is the price range for Nimodipine?
NADAC reference prices for Nimodipine range from $1.3695 to $1.3695 per EA.
Which manufacturers make Nimodipine?
2 manufacturers list Nimodipine in NADAC. Ranked by number of NDCs, the largest are Heritage Pharmaceuticals Inc. (2), Bionpharma Inc. (2).
How has the price of Nimodipine changed recently?
Over the past 7 days, 4 Nimodipine NDCs rose and 0 fell, with a market-wide average change of +9.2%.